Works matching IS 15228517 AND DT 2011 AND VI 13 AND IP 3


Results: 14
    1
    2

    Clinical trial end points for high-grade glioma: the evolving landscape*.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. 353, doi. 10.1093/neuonc/noq203
    By:
    • Reardon, David A.;
    • Galanis, Evanthia;
    • DeGroot, John F.;
    • Cloughesy, Timothy F.;
    • Wefel, Jeffrey S.;
    • Lamborn, Kathleen R.;
    • Lassman, Andrew B.;
    • Gilbert, Mark R.;
    • Sampson, John H.;
    • Wick, Wolfgang;
    • Chamberlain, Marc C.;
    • Macdonald, David R.;
    • Mehta, Minesh P.;
    • Vogelbaum, Michael A.;
    • Chang, Susan M.;
    • Van den Bent, Martin J.;
    • Wen, Patrick Y.
    Publication type:
    Article
    3
    4

    DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. 280, doi. 10.1093/neuonc/noq190
    By:
    • Zheng, Shichun;
    • Houseman, E. Andres;
    • Morrison, Zachary;
    • Wrensch, Margaret R.;
    • Patoka, Joseph S.;
    • Ramos, Christian;
    • Haas-Kogan, Daphne A.;
    • McBride, Sean;
    • Marsit, Carmen J.;
    • Christensen, Brock C.;
    • Nelson, Heather H.;
    • Stokoe, David;
    • Wiemels, Joseph L.;
    • Chang, Susan M.;
    • Prados, Michael D.;
    • Tihan, Tarik;
    • Vandenberg, Scott R.;
    • Kelsey, Karl T.;
    • Berger, Mitchel S.;
    • Wiencke, John K.
    Publication type:
    Article
    5
    6

    Cover Page.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. NP, doi. 10.1093/neuonc/nor007
    Publication type:
    Article
    7

    Editorial Board.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. NP, doi. 10.1093/neuonc/nor008
    Publication type:
    Article
    8
    9

    Subscription Page.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. NP, doi. 10.1093/neuonc/nor009
    Publication type:
    Article
    10

    Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. 324, doi. 10.1093/neuonc/noq157
    By:
    • Sampson, John H.;
    • Aldape, Kenneth D.;
    • Archer, Gary E.;
    • Coan, April;
    • Desjardins, Annick;
    • Friedman, Allan H.;
    • Friedman, Henry S.;
    • Gilbert, Mark R.;
    • Herndon, James E.;
    • McLendon, Roger E.;
    • Mitchell, Duane A.;
    • Reardon, David A.;
    • Sawaya, Raymond;
    • Schmittling, Robert;
    • Shi, Weiming;
    • Vredenburgh, James J.;
    • Bigner, Darell D.;
    • Heimberger, Amy B.
    Publication type:
    Article
    11
    12
    13
    14

    Society news.

    Published in:
    Neuro-Oncology, 2011, v. 13, n. 3, p. 362, doi. 10.1093/neuonc/nor006
    Publication type:
    Article